Ionis Pharmaceuticals (Nasdaq:IONS) - Hisse Senedi Fiyatı, Haberler ve Analizler

IONS Stoklara Genel Bakış

Ionis Pharmaceuticals, Inc. Amerika Birleşik Devletleri'nde RNA-hedefli terapötikleri keşfeder ve geliştirir.

IONS temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Gelirin yılda 21.37% oranında artması öngörülüyor

Risk Analizi

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

Ionis Pharmaceuticals, Inc. Rakipler

Abcam

NasdaqGS:ABCM

US$5.5b

Alvotech

NasdaqGM:ALVO

US$3.8b

Ultragenyx Pharmaceutical

NasdaqGS:RARE

US$4.7b

Alkermes

NasdaqGS:ALKS

US$4.7b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Ionis Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$38.46
52 Haftanın En Yüksek Seviyesi	US$54.44
52 Haftanın En Düşük Seviyesi	US$35.95
Beta	0.38
11 Aylık Değişim	1.75%
3 Aylık Değişim	-17.38%
1 Yıllık Değişim	-18.71%
33 Yıllık Değişim	14.60%
5 Yıllık Değişim	-33.45%
Halka arzdan bu yana değişim	284.60%

Son Haberler & Güncellemeler

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

Recent updates

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Oct 23

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Aug 24

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

Aug 11

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Jul 28

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

May 28

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

May 09

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Apr 14

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Mar 18

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Feb 23

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Dec 28

Hissedar Getirileri

	IONS	US Biotechs	US Pazar
7D	0.2%	4.3%	5.1%
1Y	-18.7%	29.2%	37.7%

Getiri vs. Endüstri: IONS geçen yıl % 29.2 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: IONS geçen yıl % 37.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is IONS's price volatile compared to industry and market?
IONS volatility
IONS Average Weekly Movement	5.3%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: IONS son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: IONS 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1989	927	Brett Monia	www.ionispharma.com

Ionis Pharmaceuticals, Inc. Amerika Birleşik Devletleri'nde RNA-hedefli terapötikleri keşfeder ve geliştirir. Şirket, pediatrik ve yetişkin hastalarda spinal musküler atrofi (SMA) için SPINRAZA; yetişkinlerde kalıtsal transtiretin amiloidozunun neden olduğu polinöropatinin tedavisi için bir antisens enjeksiyon olan TEGSEDI; ve ailesel şilomikronemi sendromu (FCS) ve ailesel kısmi lipodistrofi tedavisi için bir antisens ilaç olan WAYLIVRA'yı sunmaktadır. Ayrıca, tüm ATTR tiplerini tedavi etmek için aylık kendi kendine uygulanan subkutan enjeksiyon olarak Eplontersen; FCS ve şiddetli hipertrigliseridemi (SHTG) hastaları için Olezarsen; kalıtsal anjiyoödem hastaları için Donidalorsen dahil olmak üzere faz 3 çalışmasında olan çeşitli endikasyonlar için ilaçlar geliştirmektedir; Amiyotrofik lateral skleroz hastaları için ION363; süperoksit dismutaz 1 üretimini inhibe etmek için Tofersen; yerleşik kardiyovasküler hastalığı ve yüksek lipoprotein (a) olan hastalar için Pelacarsen; ve hepatit B virüsü ile ilişkili viral proteinlerin üretimini inhibe etmek için Bepirovirsen.

Ionis Pharmaceuticals, Inc. Temel Bilgiler Özeti

Ionis Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IONS temel i̇stati̇sti̇kler
Piyasa değeri	US$6.15b
Kazançlar(TTM)	-US$359.29m
Gelir(TTM)	US$803.65m

7.5x

P/S Oranı

-16.9x

F/K Oranı

IONS aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IONS gelir tablosu (TTM)
Gelir	US$803.65m
Gelir Maliyeti	US$921.10m
Brüt Kâr	-US$117.45m
Diğer Giderler	US$241.84m
Kazançlar	-US$359.29m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.28
Brüt Marj	-14.61%
Net Kâr Marjı	-44.71%
Borç/Özkaynak Oranı	274.5%

IONS uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

IONS Stoklara Genel Bakış

Ödüller

Risk Analizi

Ionis Pharmaceuticals, Inc. Rakipler

NasdaqGS:ABCM

US$5.5b

NasdaqGM:ALVO

US$3.8b

NasdaqGS:RARE

US$4.7b

NasdaqGS:ALKS

US$4.7b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Ionis Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $500.25 million.

There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding

Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2024

Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?

Ionis Pharmaceuticals, Inc. Announces Positive Detailed Results from the HALOS Study of ION582 in People with Angelman Syndrome

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed

Independent Director notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema

Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Lead Independent Director exercised options to buy US$612k worth of stock.

Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Founder recently sold US$1.2m worth of stock

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Insider notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Senior Strategic Advisor & Director notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Founder notifies of intention to sell stock

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

Founder notifies of intention to sell stock